Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexpramipexole in eosinophilic COPD
NCT06533553Phase 2Active, not recruiting
- Sponsor
- Areteia Therapeutics
- Start
- Jul 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dexpramipexole in chronic obstructive pulmonary disease (COPD), sponsored by Areteia Therapeutics. Primary endpoint: Blood Absolute Eosinophil Count at Week 16. Started Jul 2024; status: active, not recruiting.
02
Drugs
dexpramipexole
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06533553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06533553.